Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Boothman
Indiana Univ Purdue Univ at Indianapolis, Department: Biochemistry
Should you be removed from our database? Contact us at [email protected]. Read more below.
Toray
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Dr. Boothman serves as a consultant for Toray who has licensed NQO1 bioactivatable drug, IB-DNQ, owned by Investigator and Dr. Paul Hergenrother and licensed by their then current institutions. Toray is developing the drug through an IND for clinical trials in 2018. The NIH award uses NQO1 bioactivatable drugs. Dr. Boothman previously conducted this consulting for Systems Oncology. They recently licensed their interest to Toray. Dr. Boothman now conducts the same consulting for Toray instead of Systems Oncology.
Tumor-selective radiosensitization of NSCLC using NQO1 bioactivatable drugs
Project Narrative / Lay statement Nonsmall cell lung cancers have inherent cancer vulnerabilities, such as the need to over-express specific enzymes, such as NAD(P)H:quinone Oxidoreductase 1 (NQO1), for their survival. We are developing tumor-selective therapies using unique compounds that are over-metabolized by NQO1 in a manner that ultimately kills lung cancers (specifically NSCLC), but have no affects on normal tissue. We will develop cancer- selective strategies of therapy using ionizing radiation and unique NQO1 bioactivatable drugs, such as �-lapachone (in clinical trials as ARQ761 now at UTSW and Johns Hopkins University) and isobutyldeoxynyboquinone (IB-DNQ), where we believe a clinical trial will begin within 5 years.
Filed on September 07, 2018.
Tell us what you know about David Boothman's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
David Boothman filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Boothman | Indiana Univ Purdue Univ at Indianapolis | Conflict of Interest | Toray | $40,000 - $59,999 |
| David Boothman | Indiana Univ Purdue Univ at Indianapolis | Conflict of Interest | Systems Oncology | $40,000 - $59,999 |
| David Boothman | Indiana Univ Purdue Univ at Indianapolis | Conflict of Interest | Systems Oncology | $40,000 - $59,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.